Miles Wang leaves OpenAI to start a new AI-powered drug discovery company, expected to raise $200 million at a $2 billion valuation.
Why it matters
This article highlights the growing trend of AI applications in life sciences, with startups competing to develop innovative AI-powered solutions for drug discovery and existing use cases.
No community posts found
Check back soon for discussions